Big Pharma’s “Value” M&As – Buying Cheap in Growth Industry Generally Does Not Work
This morning, we saw some interesting transaction coming out of a major European Pharma - GlaxoSmithKlein annnouced a global collaboration in immuno-neurology for neuro-degenerative disease with Alector for $700mm upfront…